Alyeska Investment Group L.P. Sells 187,550 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

Alyeska Investment Group L.P. lessened its holdings in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 42.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 253,468 shares of the company’s stock after selling 187,550 shares during the period. Alyeska Investment Group L.P.’s holdings in Nautilus Biotechnology were worth $426,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Virtu Financial LLC bought a new position in Nautilus Biotechnology during the 4th quarter worth $28,000. SG Americas Securities LLC lifted its position in Nautilus Biotechnology by 56.3% during the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares during the period. Palumbo Wealth Management LLC grew its stake in Nautilus Biotechnology by 45.4% during the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after buying an additional 8,888 shares in the last quarter. Hsbc Holdings PLC increased its holdings in Nautilus Biotechnology by 182.5% in the 4th quarter. Hsbc Holdings PLC now owns 55,184 shares of the company’s stock valued at $92,000 after buying an additional 35,650 shares during the period. Finally, Barclays PLC raised its position in shares of Nautilus Biotechnology by 79.6% in the 3rd quarter. Barclays PLC now owns 106,174 shares of the company’s stock valued at $303,000 after buying an additional 47,059 shares in the last quarter. 50.71% of the stock is owned by institutional investors.

Nautilus Biotechnology Stock Down 2.5 %

Nautilus Biotechnology stock opened at $0.67 on Wednesday. The stock has a market cap of $84.25 million, a PE ratio of -1.19 and a beta of 1.41. Nautilus Biotechnology, Inc. has a 12-month low of $0.66 and a 12-month high of $3.09. The business’s 50-day moving average price is $0.89 and its two-hundred day moving average price is $1.63.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Tuesday, April 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. As a group, analysts expect that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Insider Activity

In other Nautilus Biotechnology news, CEO Sujal M. Patel acquired 53,300 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The stock was acquired at an average price of $0.99 per share, for a total transaction of $52,767.00. Following the acquisition, the chief executive officer now directly owns 10,117,788 shares in the company, valued at $10,016,610.12. This represents a 0.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 40.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Separately, Guggenheim set a $2.50 price objective on shares of Nautilus Biotechnology in a research report on Friday, February 28th.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.